BAPTIST BEAUMONT HOSPITAL
- Type
- Teaching hospital
- Where
- Beaumont, TX
- Medicare CCN
- 450346
- Received
- $83,718 in 81 records, 2024 ($11,462 general, $72,256 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 3 | $11,462 |
| 2024 | Research payment | 78 | $72,256 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Dompe Farmaceutici S.p.A. | 70 | $44,946 | 2024 |
| GlaxoSmithKline, LLC. | 8 | $27,310 | 2024 |
| AngioDynamics, Inc. | 1 | $9,833 | 2024 |
| Boston Scientific Corporation | 1 | $1,045 | 2024 |
| Fisher & Paykel Healthcare Inc | 1 | $583 | 2024 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 78 | $72,256 |
| Long term medical supply or device loan | 3 | $11,462 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | AngioDynamics, Inc. | $9,833 | Long term medical supply or device loan | In-kind items and services | Auryon Laser System 100-120 Vac Device, ET | 2024 | |
| 2024-12-31 | Fisher & Paykel Healthcare Inc | $583 | Long term medical supply or device loan | In-kind items and services | FISHER & PAYKEL HEALTHCARE Device, Heated respiratory humidifier | 2024 | |
| 2024-12-02 | GlaxoSmithKline, LLC. | $7,295 | Research payment | Cash or cash equivalent | A PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL | 2024 | |
| 2024-12-02 | GlaxoSmithKline, LLC. | $763 | Research payment | Cash or cash equivalent | A PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL | 2024 | |
| 2024-09-11 | Dompe Farmaceutici S.p.A. | $987 | Research payment | Cash or cash equivalent | "Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised | 2024 | |
| 2024-09-11 | Dompe Farmaceutici S.p.A. | $987 | Research payment | Cash or cash equivalent | "Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised | 2024 | |
| 2024-09-11 | Dompe Farmaceutici S.p.A. | $987 | Research payment | Cash or cash equivalent | "Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised | 2024 | |
| 2024-09-11 | Dompe Farmaceutici S.p.A. | $654 | Research payment | Cash or cash equivalent | "Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised | 2024 | |
| 2024-09-06 | GlaxoSmithKline, LLC. | $3,649 | Research payment | Cash or cash equivalent | A PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL | 2024 | |
| 2024-09-06 | GlaxoSmithKline, LLC. | $2,371 | Research payment | Cash or cash equivalent | A PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL | 2024 | |
| 2024-09-06 | GlaxoSmithKline, LLC. | $733 | Research payment | Cash or cash equivalent | A PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL | 2024 | |
| 2024-08-13 | Boston Scientific Corporation | $1,045 | Long term medical supply or device loan | In-kind items and services | Rezum Device, Rezum | 2024 | |
| 2024-07-24 | Dompe Farmaceutici S.p.A. | $1,307 | Research payment | Cash or cash equivalent | "Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised | 2024 | |
| 2024-07-24 | Dompe Farmaceutici S.p.A. | $1,307 | Research payment | Cash or cash equivalent | "Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised | 2024 | |
| 2024-07-24 | Dompe Farmaceutici S.p.A. | $1,279 | Research payment | Cash or cash equivalent | "Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised | 2024 | |
| 2024-07-24 | Dompe Farmaceutici S.p.A. | $1,241 | Research payment | Cash or cash equivalent | "Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised | 2024 | |
| 2024-07-24 | Dompe Farmaceutici S.p.A. | $1,089 | Research payment | Cash or cash equivalent | "Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised | 2024 | |
| 2024-07-24 | Dompe Farmaceutici S.p.A. | $1,089 | Research payment | Cash or cash equivalent | "Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised | 2024 | |
| 2024-07-24 | Dompe Farmaceutici S.p.A. | $750 | Research payment | Cash or cash equivalent | "Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised | 2024 | |
| 2024-06-19 | Dompe Farmaceutici S.p.A. | $1,279 | Research payment | Cash or cash equivalent | "Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised | 2024 | |
| 2024-06-19 | Dompe Farmaceutici S.p.A. | $1,279 | Research payment | Cash or cash equivalent | "Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised | 2024 | |
| 2024-06-19 | Dompe Farmaceutici S.p.A. | $1,241 | Research payment | Cash or cash equivalent | "Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised | 2024 | |
| 2024-06-19 | Dompe Farmaceutici S.p.A. | $1,241 | Research payment | Cash or cash equivalent | "Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised | 2024 | |
| 2024-06-19 | Dompe Farmaceutici S.p.A. | $1,089 | Research payment | Cash or cash equivalent | "Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised | 2024 | |
| 2024-06-19 | Dompe Farmaceutici S.p.A. | $1,089 | Research payment | Cash or cash equivalent | "Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised | 2024 | |
| 2024-06-19 | Dompe Farmaceutici S.p.A. | $987 | Research payment | Cash or cash equivalent | "Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised | 2024 | |
| 2024-06-19 | Dompe Farmaceutici S.p.A. | $987 | Research payment | Cash or cash equivalent | "Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised | 2024 | |
| 2024-06-19 | Dompe Farmaceutici S.p.A. | $987 | Research payment | Cash or cash equivalent | "Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised | 2024 | |
| 2024-06-19 | Dompe Farmaceutici S.p.A. | $950 | Research payment | Cash or cash equivalent | "Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised | 2024 | |
| 2024-06-19 | Dompe Farmaceutici S.p.A. | $750 | Research payment | Cash or cash equivalent | "Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised | 2024 | |
| 2024-06-19 | Dompe Farmaceutici S.p.A. | $116 | Research payment | Cash or cash equivalent | "Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised | 2024 | |
| 2024-06-12 | Dompe Farmaceutici S.p.A. | $1,661 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-05-17 | Dompe Farmaceutici S.p.A. | $1,389 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-05-17 | Dompe Farmaceutici S.p.A. | $944 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-05-17 | Dompe Farmaceutici S.p.A. | $944 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-05-01 | Dompe Farmaceutici S.p.A. | $25 | Research payment | Cash or cash equivalent | "Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised | 2024 | |
| 2024-05-01 | Dompe Farmaceutici S.p.A. | $25 | Research payment | Cash or cash equivalent | "Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised | 2024 | |
| 2024-04-10 | Dompe Farmaceutici S.p.A. | $1,375 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-04-05 | Dompe Farmaceutici S.p.A. | $1,727 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-04-05 | Dompe Farmaceutici S.p.A. | $1,661 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-04-05 | Dompe Farmaceutici S.p.A. | $1,655 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-04-05 | Dompe Farmaceutici S.p.A. | $1,456 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-04-05 | Dompe Farmaceutici S.p.A. | $1,389 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-04-05 | Dompe Farmaceutici S.p.A. | $1,389 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-04-05 | Dompe Farmaceutici S.p.A. | $1,389 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-04-05 | Dompe Farmaceutici S.p.A. | $1,279 | Research payment | Cash or cash equivalent | "Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised | 2024 | |
| 2024-04-05 | Dompe Farmaceutici S.p.A. | $1,279 | Research payment | Cash or cash equivalent | "Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised | 2024 | |
| 2024-04-05 | Dompe Farmaceutici S.p.A. | $944 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-03-27 | GlaxoSmithKline, LLC. | $2,016 | Research payment | Cash or cash equivalent | NUCALA Biological, IMMUNOLOGY | A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT | 2024 |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | $28 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | $28 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | $28 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | $28 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | $28 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | $17 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | $17 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | $17 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | $17 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | $17 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | $17 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | $17 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | $17 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | $17 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | $17 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | $17 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | $17 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | $17 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | $17 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | $17 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | $17 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | $17 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | $17 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | $17 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | $17 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | $17 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-02-01 | GlaxoSmithKline, LLC. | $8,377 | Research payment | Cash or cash equivalent | A PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL | 2024 | |
| 2024-02-01 | GlaxoSmithKline, LLC. | $2,102 | Research payment | Cash or cash equivalent | A PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL | 2024 | |
| 2024-01-04 | Dompe Farmaceutici S.p.A. | $100 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-01-04 | Dompe Farmaceutici S.p.A. | $43 | Research payment | Cash or cash equivalent | "Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised | 2024 | |
| 2024-01-04 | Dompe Farmaceutici S.p.A. | $43 | Research payment | Cash or cash equivalent | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 | |
| 2024-01-04 | Dompe Farmaceutici S.p.A. | $28 | Research payment | Cash or cash equivalent | "Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Beaumont, TX, county Jefferson County, TX, state Texas; placed by its city name.
| Measure | Place (city or town) Beaumont, TX | County Jefferson County, TX | State Texas |
|---|---|---|---|
| Population B01003 | 113,279 | 253,878 | 30,188,424 |
| Population, 2020 census P1 | 115,282 | 256,526 | 29,145,505 |
| Median age B01002 | 35.3 | 37.0 | 35.6 |
| Under 18 B01001 | 25.3% | 24.6% | 25.0% |
| 65 and over B01001 | 16.3% | 15.5% | 13.4% |
| Households B11001 | 45,001 | 94,807 | 10,992,816 |
| Foreign born B05002 | 11.0% | 12.1% | 17.6% |
| Median household income B19013 | $56,997 | $60,026 | $78,476 |
| Median family income B19113 | $71,096 | $75,099 | $94,599 |
| Per capita income B19301 | $32,642 | $32,101 | $40,752 |
| Poverty rate B17001 | 21.2% | 19.5% | 13.8% |
| Unemployment rate B23025 | 6.4% | 6.3% | 5.3% |
| Civilian labor force B23025 | 52,630 | 110,898 | 15,233,563 |
| Mean commute (minutes) B08013 | 20.3 | 21.2 | 26.7 |
| Bachelor's degree or higher B15003 | 24.9% | 19.7% | 33.8% |
| Housing units B25001 | 52,439 | 109,884 | 12,128,515 |
| Owner-occupied B25003 | 55.3% | 62.5% | 62.6% |
| Renters B25003 | 44.7% | 37.5% | 37.4% |
| Median home value B25077 | $166,400 | $169,500 | $283,800 |
| Median gross rent B25064 | $1,121 | $1,117 | $1,403 |
| White, not Hispanic B03002 | 26.3% | 36.3% | 39.1% |
| Black B03002 | 45.2% | 32.7% | 11.9% |
| Hispanic or Latino B03002 | 20.8% | 24.1% | 39.7% |
| Asian B03002 | 3.8% | 3.8% | 5.5% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Beaumont, TX.
Comments